Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
AI Chat Bot for Websites
sajith.xp.pk
Updated:
Thursday at 1:17 PM
Puffin Rock Characters Plush Toy Set
anil1961
Updated:
Nov 7, 2026
Toyota Vitz scp10 For Sale
Lakmal Bandara
Updated:
Nov 4, 2026
Kandy
Welcome all my all new pet shop Bark.lk
dilumrane
Updated:
Nov 2, 2026
Windows RDP Only Rs.500 a month
Blogerwiki
Updated:
Nov 1, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
'Landmark moment' - Aussie led mRNA melanoma vaccine breakthrough
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 31672568" data-attributes="member: 562115"><p>A world-first mRNA cancer vaccine has dramatically cut the risk of melanoma recurrence and death in a landmark large-scale trial that signals a new era in personalised cancer medicine.</p><p></p><p>The Australian-led phase 3 trial found that adding a tailor-made cancer vaccine reduced the risk of the recurrence of melanoma or death by 42 per cent, compared with patients who were only given the immunotherapy drug, pembrolizumab (sold as Keytruda).</p><p></p><p>Principal investigator Professor Georgina Long said she almost fell off her chair when she got the phone call relaying the trial results.</p><p></p><p>“I’m not one prone to exaggeration, but this really is a very, very big leap forward in cancer,” said Long, who pioneered immunotherapy treatments that transformed melanoma from a death sentence to a treatable disease.</p><p></p><p>“It’s all the clichés: landmark moment, moon landing, first flight – it really is a foundational shift,” she said from her apartment in Lisbon, Portugal, on sabbatical from her medical director role at the Melanoma Institute Australia, affiliated with the University of Sydney.</p><p></p><p>Trial participants had all previously undergone surgery to remove their melanoma tumours. All 1137 were given pembrolizumab. Two-thirds were also given the personalised mRNA therapeutic vaccine designed to enable their immune system to recognise and destroy their distinct cancer cells, while the remaining patients were given a placebo injection.</p><p></p><p><strong>The trial, funded by Merck and Moderna, found that, at two years, 82 per cent of trial patients who received both treatments were alive and melanoma-free, compared with 70 per cent of those who received pembrolizumab alone.</strong></p></blockquote><p></p>
[QUOTE="imhotep, post: 31672568, member: 562115"] A world-first mRNA cancer vaccine has dramatically cut the risk of melanoma recurrence and death in a landmark large-scale trial that signals a new era in personalised cancer medicine. The Australian-led phase 3 trial found that adding a tailor-made cancer vaccine reduced the risk of the recurrence of melanoma or death by 42 per cent, compared with patients who were only given the immunotherapy drug, pembrolizumab (sold as Keytruda). Principal investigator Professor Georgina Long said she almost fell off her chair when she got the phone call relaying the trial results. “I’m not one prone to exaggeration, but this really is a very, very big leap forward in cancer,” said Long, who pioneered immunotherapy treatments that transformed melanoma from a death sentence to a treatable disease. “It’s all the clichés: landmark moment, moon landing, first flight – it really is a foundational shift,” she said from her apartment in Lisbon, Portugal, on sabbatical from her medical director role at the Melanoma Institute Australia, affiliated with the University of Sydney. Trial participants had all previously undergone surgery to remove their melanoma tumours. All 1137 were given pembrolizumab. Two-thirds were also given the personalised mRNA therapeutic vaccine designed to enable their immune system to recognise and destroy their distinct cancer cells, while the remaining patients were given a placebo injection. [B]The trial, funded by Merck and Moderna, found that, at two years, 82 per cent of trial patients who received both treatments were alive and melanoma-free, compared with 70 per cent of those who received pembrolizumab alone.[/B] [/QUOTE]
Insert quotes…
Verification
Payakata winadi keeyak tibeda?
Post reply
Top
Bottom